Tracer library / [177Lu]Lu-DOTA-DV1-K-DV3

[177Lu]Lu-DOTA-DV1-K-DV3

Also written as [Lu-177]Lu-DOTA-DV1-K-DV3; [Lu-177]Lu-DOTA-DV1-k-(DV3

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 2

Glioma and brain tumours Other radioligand therapy

What it is

Compound class: DOTA-conjugated D-amino acid-based peptide targeting CXCR4
Target / mechanism: CXCR4 (C-X-C chemokine receptor 4) antagonist/binder PMID 34683912
Clinical application: Glioblastoma (GBM) targeted radionuclide therapy PMID 39008219
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>95%	>95%	DOTA-DV1-K-DV3 CSBio, California, US	39008219 2024 EJNMMI Radiopharm Chem [177Lu]LuCl3 was added to the DOTA-conjugated peptides in 0.15 M NaOAc buffer, pH 4.7, with a total reaction volume of 0.25–0.35 mL, and reacted at 95 °C for 30 min with gentle shaking - All three DOTA-conjugated peptides could be radiolabelled with 177Lu with > 95% radiochemical yield.
Manual synthesis	—	—	>98%	>98%	DOTA-DV1-k-(DV3) Pepmic Co., Ltd., Suzhou, China	34683912 2021 Pharmaceutics Labeling of DOTA-DV1-k-(DV3) with [177Lu]LuCl3 was carried out manually (RCY > 98% (n = 3), RCP > 98%, Figure S22). - Labeling of DOTA-DV1-k-(DV3) with [177Lu]LuCl3 was carried out manually (RCY > 98% (n = 3), RCP > 98%, Figure S22).

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: CSBio, Pepmic Co., Ltd.
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-DV1-K-DV3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39008219: 'DOTA-CTCE9908, DOTA-DV1-K-DV3, and DOTA-POL3026 were obtained from the custom peptide synthesis service of CSBio (California, US)'. Stage set/updated at stage 39 from PMID 39008219: 'Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.'.